// App-Quantinova.ai

TPS9138 : An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).

Researchers

Presenter

  • Mariam Jamal-Hanjani

Principal Investigators

  • Alastair Greystoke

  • Fiona Thistlethwaite

  • Yvonne J. Summers

  • Jennifer Allison

  • Judith Cave

  • Kim Orchard

  • Christian Ottensmeier

  • Gary Middleton

  • Leila Khoja

  • Michael Grant

  • Shreenal Patel

  • Jane Robertson

  • Karl Peggs

  • Martin Forster

Medical Centers

  • Kings College London, London, United Kingdom

  • Freeman Hospital, Newcastle upon Tyne, United Kingdom

  • The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Southampton University Hospitals NHS Trust, Southhampton, United Kingdom

  • University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

  • Cancer Research UK, Southampton, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Achilles Therapeutics Ltd, London, United Kingdom

  • University College London Hospitals NHS Trust, London, United Kingdom

Locations

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Programmed cell death protein 1

  • Interleukin-2

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Pembrolizumab

  • fludarabine tablet

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Cohort

  • First-In-Human

Phase

  • I/II

Study Id's

  • NCT03517917

  • NCT04032847

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved